Search
Thromboembolic event
go.drugbank.com/conditions/DBCOND0024072Synonyms: Embolism and thrombosis of unspecified siteAlcohol Withdrawal Associated Autonomic Hyperactivity
go.drugbank.com/conditions/DBCOND0052442Synonyms: [X]Mental and behavioral disorders due to use of alcohol: withdrawal state with delirium (disorder)Telotristat ethyl
go.drugbank.com/drugs/DB12095Approved[A252947] The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. … [A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET.
Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine
go.drugbank.com/drugs/DB03771ExperimentalEI-001
go.drugbank.com/drugs/DB17596InvestigationalSynonyms: Human monoclonal antibody based on an IgG1 lambda framework against human interferon gammaRespiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals.
Atrial natriuretic peptide
go.drugbank.com/drugs/DB15591InvestigationalSynonyms: ANPCategories: Amino Acids, Peptides, and Proteins, Hormones, Hormone Substitutes, and Hormone AntagonistsSerplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalSerplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor. … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.
Categories: Antineoplastic and Immunomodulating Agents, Monoclonal antibodies and antibody drug conjugatesMaralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalMaralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like [odevixibat]. … [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541]
Categories: Bile and Liver Therapy, Alimentary Tract and Metabolism